266 results on '"Scordo M"'
Search Results
2. Evolving consolidation patterns and modern outcomes for a large longitudinal cohort of primary CNS lymphoma patients
3. DYNAMICS OF RADIOMIC FEATURES FOLLOWING BRIDGING THERAPY DETERMINE CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T‐CELL THERAPY OUTCOME
4. Radiotherapy as an effective bridge for chemo‐refractory or progressive secondary CNS lymphoma
5. OC-0439 Consolidation patterns and associated outcomes for a large cohort of primary CNS lymphoma patients
6. Population differences in S-warfarin pharmacokinetics among African Americans, Asians and whites: their influence on pharmacogenetic dosing algorithms
7. Kaonic atoms experiment at the DAΦNE collider by SIDDHARTA/SIDDHARTA-2
8. OC-0438 Patterns of failure in 559 primary central nervous system lymphoma patients treated from 1983-2020
9. Radiotherapy for Relapse after Chimeric Antigen Receptor T Cell Therapy in Hematologic Malignancies
10. Patterns of Relapse and Risk Reduction Following Tumor Debulking by Bridging Radiotherapy prior to Chimeric Antigen Receptor T Cell Therapy in Non-Hodgkin Lymphoma
11. A Proof-of-Principle Study of Split-Course Bridging Radiotherapy (SC-BRT) prior to Commercial CAR T-Cell Therapies for Relapsed or Refractory B-Cell Lymphomas: Results from Phase 1a Pilot Cohort
12. Improvement in Radiomic Features Following Bridging Therapy is Prognostic for CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy Outcome
13. The Association of Consolidation Strategies with Cerebral Atrophy in Primary Central Nervous System Lymphoma (PCNSL)
14. Patterns of Intracranial Response and Relapse after Radiotherapy for Patients with Chemorefractory or Progressive Secondary CNS Lymphoma
15. S177: EVALUATING SERUM FREE LIGHT CHAIN RATIO AS A BIOMARKER FOR MULTIPLE MYELOMA
16. P886: AFRICAN AMERICAN PATIENTS WITH SMOLDERING MULTIPLE MYELOMA MAY HAVE A LOWER RISK OF PROGRESSION COMPARED TO WHITE PATIENTS
17. P1344: METHODOLOGY OF AN INTERNATIONAL MULTI-CENTER RETROSPECTIVE REVIEW OF TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (TA-TMA) BY THE TA-TMA WORKING GROUP
18. CNS radiotherapy as bridging prior to CAR T‐cell therapy for hematologic malignancies.
19. IMPACT OF RESPONSE TO SYSTEMIC BRIDGING THERAPY ON CLINICAL OUTCOMES AND CYTOKINE PROFILE IN PATIENTS RECEIVING CAR T‐CELL THERAPY FOR AGGRESSIVE B‐CELL LYMPHOMA.
20. Anderson-Fabry disease with cerebrovascular complications in two Italian families
21. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics
22. FMO3 polymorphisms in 13 ethnic populations: frequency and linkage analysis: YSF-57
23. Apo-E genotype and donepezil therapeutic outcome in patients with Alzheimerʼs disease: 148
24. Genetic polymorphisms of CYP2C8 and CYP2C9 influence diurnal blood pressure parameters in elderly subjects: 147
25. A PK-PD Model for Predicting the Impact of Age, CYP2C9, and VKORC1 Genotype on Individualization of Warfarin Therapy
26. MSKCC EARLY EXPERIENCE USING RADIOTHERAPY AS A BRIDGING STRATEGY FOR RELAPSED DIFFUSE LARGE B CELL LYMPHOMA BEFORE CD19 CAR T THERAPY
27. HIGHLY FAVORABLE OUTCOMES WITH RT FOLLOWED BY ASCT IN LOW/LOW-INTERMEDIATE SECONDARY AGE ADJUSTED IPI REL/REF DLBCL PATIENTS REFRACTORY TO SALVAGE CHEMOTHERAPY
28. Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects
29. Patients with Relapsed/Refractory Large Cell Lymphoma Who Were Also Refractory to Salvage Chemotherapy: Outcome with Salvage Radiation Therapy Followed by Autologous Stem Cell Transplant
30. Patterns of disease failure by response to induction therapy in a large cohort of patients with primary central nervous system lymphoma.
31. The first step in the managment and replacement strategy of water distribution network: the analisys of main failures
32. Population differences in S-warfarin pharmacokinetics among African Americans, Asians and whites: their influence on pharmacogenetic dosing algorithms
33. Genetic polymorphisms of CYP2C8 and CYP2C9 influence diurnal blood pressure parameters in elderly subjects
34. Farmakogenetiska faktorer som influerar plasmanivåerna av risperidon och dess aktiva metabolit
35. Impact of CYP3A4 polymorphisms on donepezil plasma levels and therapeutic outcome
36. Impact of CYP3A4 and CYP3A5 polymorphisms on clinical outcome of donepezil in Alzheimer’s disease patients
37. Impact of Apo-E genotype on the response to donepezil therapy in patients with Alzheimer’s Disease
38. Dopamine D2 and D3 receptor gene polymorphisms and clinical outcome of risperidone therapy in schizophrenic patients
39. Serotonin 2C receptor gene polymorphisms in association with extrapyramidal side-effects in schizophrenic patients
40. Clinical impact of 5-HT2A polymorphisms on risperidone therapeutic outcome in schizophrenic patients
41. Effects of CYP3A4 interacting drugs on donepezil plasma levels in patients with Alzheimer’s disease
42. Clinical impact of CYP2D6 polymorphism in patients with Alzheimer's disease in therapy with donepezil
43. CYP2D6*4 genotyping: a comparative study between two different PCR/RFLP methods
44. Aprataxin Mutations in Italian Patients with Ataxia and Oculomotor Apraxia (AOA)
45. Impact of CYP2D6 polymorphism on plasma levels of donepezil: clinical relevance in patients with Alzheimer’s disease
46. Caratterizzazione molecolare di pazienti italiani affetti da Atassia con Aprassia Oculomotoria di tipo 1 (AOA1)
47. Drug Interactions in Epilepsy
48. Influence of cytochrome P450s 2C9 and 2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance
49. Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes
50. A shifting level model algorithm that identifies aberrations in array-CGH data
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.